Hemagglutinin (HA) is a glycoprotein present in the membrane of influenza virus. HA exists as a trimer and each monomer at its membrane tip has receptor-binding site. Glycosylation event of HA occurs in endoplasmic reticulum. The head region with the receptor-binding site of the HA is variable. The mouse monoclonal Anti-HA, Clone HA-7 recognizes the human influenza virus hemagglutinin (HA), known as the HA tag. The product is reactive with HA-tagged fusion proteins expressed at either the amino or the carboxy terminus of the fusion protein.
The antibody recognizes native as well as denatured-reduced forms of HA-tagged proteins and is reactive with N- or C-terminal HA-tagged fusion proteins expressed in E. coli or in mammalian cells.
synthetic peptide corresponding to a fragment of human influenza virus hemagglutinin (HA) known as HA-tag, conjugated to KLH
Monoclonal Anti-HA antibody produced in mouse has been used:
- in immunoblotting
- in immunocytochemistry
- in the immunoprecipitation
Hemagglutinin (HA) binds to acid binding and is essential for the initiation of virus infection. It is the key target for the generation of vaccine. HA is the dominant antigen against which humoral immune response is provoked. Vaccines development involves the generation of antibody specific to the variable head and the conserved stalk region. Both the anti-stalk and anti-head antibodies may elicit protective function in influenza disease.
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 1% BSA and 15 mM sodium azide as a preservative.